Moreover, a slow-release ATRA formulation induces the degradation of PIN1 and decreases tumorigenicity in mice xenograft model of HCC (Wei et al., 2015; Liao P. et al., 2017). The gene discussed is PIN1; the disease is hepatocellular carcinoma.